Evolut PRO 中国臨床試験
Medtronic CoreValve™ Evolut™ PRO システムの中国での臨床試験
Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).
調査の概要
詳細な説明
The study is targeting 6 centers with a maximum of 8 centers in China and estimating 65 subjects with a maximum of up to 70 subjects with attempted implants including 50 subjects with an attempted implant in primary study population and the first two attempted subjects at each site for roll-in population. The subjects will follow the assessment with pre and post-procedure, discharge, 30 days(primary endpoint), 6 months, 1 year, and annually through 5 years.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100000
- Chinese PLA General Hospital, Chinese PLA Medical School
-
Beijing、Beijing Municipality、中国、100000
- Beijing Anzhen Hospital, Capital Medical University
-
-
Sichuan
-
Chengdu、Sichuan、中国、610000
- West China Hospital of Sichuan University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310009
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aortic valve area (AVA) < 1.0 cm2 (or indexed AVA <0.6 cm2/m2) OR mean gradient > 40 mmHg, OR max aortic velocity > 4.0 m/sec
- High risk for SAVR defined as STS-PROM score ≥ 8% AND ≤ 15%, OR documented Heart Team agreement of high risk for AVR due to frailty or comorbidities
- Symptoms of aortic stenosis and NYHA ≥ II
Exclusion Criteria:
- Age is less than 65 years old
- Non-calcified aortic valve
- Bicuspid aortic valve with no raphe or 2 raphes (Sievers classification type 0 or type 2)
- Ascending aortic diameter > 4.5 cm
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Medtronic CoreValve™ Evolut™ PRO System
The system comprised of the following three components:
|
The system comprised of the following three components:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-cause Mortality
時間枠:30 days
|
All-cause mortality at 30 days |
30 days
|
|
Percentage (%) of Subjects With Evaluable Echocardiograms With Moderate or Severe Aortic Regurgitation by Transthoracic Echocardiography (TTE)
時間枠:30 days
|
Percentage (%) of Subjects with evaluable echocardiograms with moderate or severe aortic regurgitation by transthoracic echocardiography (TTE) |
30 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of an VARC II Combined Composite
時間枠:30 days
|
Incidence of an VARC II combined composite includes the following components:
|
30 days
|
|
Event Rates of the Individual Components of the VARC II Composite
時間枠:30 days
|
Event rate of the individual components listed in the outcome |
30 days
|
|
New Permanent Pacemaker Rate
時間枠:30 days
|
New permanent pacemaker rate |
30 days
|
|
Device Success Rate
時間枠:Between 24 hours and 7 days post procedure
|
Device success rate:
|
Between 24 hours and 7 days post procedure
|
|
Valve Performance Parameter - Mean Aortic Gradient
時間枠:30 days
|
Mean aortic gradient |
30 days
|
|
Valve Performance Parameter - Effective Orifice Area
時間枠:30 days
|
Effective orifice area |
30 days
|
|
Valve Performance Parameter -Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
時間枠:30 days
|
Degree of aortic regurgitation (transvalvular, paravalvular, total) |
30 days
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Event Rates of TAVI-related Complications
時間枠:30 days
|
Rate of the following TAVI-related complications:
|
30 days
|
|
All-cause Mortality
時間枠:6 months
|
Percentage of participants with all-cause mortality |
6 months
|
|
All-cause Mortality
時間枠:1 year
|
Percentage of participants with all-cause mortality |
1 year
|
|
All Stroke
時間枠:6 months
|
Incidence of stroke (disabling and non-disabling) |
6 months
|
|
All Stroke
時間枠:1 year
|
Incidence of stroke (disabling and non-disabling) |
1 year
|
|
Myocardial Infarction
時間枠:30 days
|
Incidence of MI |
30 days
|
|
Myocardial Infarction
時間枠:6 months
|
Incidence of MI |
6 months
|
|
Myocardial Infarction
時間枠:1 Year
|
Incidence of MI |
1 Year
|
|
Incidence of Life-threatening Bleeding
時間枠:30 days
|
Incidence of life-threatening bleeding:
|
30 days
|
|
Incidence of Life-threatening Bleeding
時間枠:6 months
|
Incidence of life-threatening bleeding:
|
6 months
|
|
Incidence of Life-threatening Bleeding
時間枠:1 Year
|
Incidence of life-threatening bleeding:
|
1 Year
|
|
New AV-Conduction Disturbances (Left Bundle Branch Block (LBBB) and Right Bundle Branch Block (RBBB))
時間枠:30 days
|
Incidence of either LBBB or RBBB |
30 days
|
|
Incidence of Prosthetic Valve Endocarditis
時間枠:30 days
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
30 days
|
|
Incidence of Prosthetic Valve Endocarditis
時間枠:6 months
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
6 months
|
|
Incidence of Prosthetic Valve Endocarditis
時間枠:1 Year
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
1 Year
|
|
Incidence of Prosthetic Valve Thrombosis
時間枠:30 days
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
30 days
|
|
Incidence of Prosthetic Valve Thrombosis
時間枠:6 months
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
6 months
|
|
Incidence of Prosthetic Valve Thrombosis
時間枠:1 Year
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
1 Year
|
|
Valve-related Dysfunction
時間枠:1 Year
|
Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II) |
1 Year
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:30 days
|
Incidence of Valve-related dysfunction requiring repeat procedure |
30 days
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:6 months
|
Incidence of Valve-related dysfunction requiring repeat procedure |
6 months
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:1 Year
|
Incidence of Valve-related dysfunction requiring repeat procedure |
1 Year
|
|
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
時間枠:1 year
|
Mean aortic gradient |
1 year
|
|
Valve Hemodynamic Performance Metric - Effective Orifice Area
時間枠:1 year
|
Effective orifice area |
1 year
|
|
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
時間枠:1 year
|
Degree of aortic regurgitation (transvalvular, paravalvular, total) |
1 year
|
|
New York Heart Association (NYHA) Functional Classification
時間枠:30 days
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
30 days
|
|
New York Heart Association (NYHA) Functional Classification
時間枠:6 month
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
6 month
|
|
New York Heart Association (NYHA) Functional Classification
時間枠:1 Year
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
1 Year
|
|
EQ-5D Quality of Life
時間枠:30 days
|
EuroQol Group developed this Quality of Life (QOL) questionnaire referred to as EQ-5D that includes a descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The answers given to ED-5D can be converted into EQ-5D index and utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D Index Score is calculated for each study participant and the descriptive statistical summary of the EQ-5D score for the study population is provided. The EQ-5D Visual Analog Scale (VAS) Score is a scale numbered 0 to 100 (0 is the worse health the patient can imagine and 100 is the best health the patient can imagine). |
30 days
|
|
EQ-5D Quality of Life
時間枠:1 Year
|
EuroQol Group developed this Quality of Life (QOL) questionnaire referred to as EQ-5D that includes a descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The answers given to ED-5D can be converted into EQ-5D index and utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D Index Score is calculated for each study participant and the descriptive statistical summary of the EQ-5D score for the study population is provided. The EQ-5D Visual Analog Scale (VAS) Score is a scale numbered 0 to 100 (0 is the worse health the patient can imagine and 100 is the best health the patient can imagine). |
1 Year
|
|
All-cause Mortality
時間枠:2 year
|
Percentage of participants with all-cause mortality |
2 year
|
|
All Stroke
時間枠:2 year
|
Incidence of stroke (disabling and non-disabling) |
2 year
|
|
Myocardial Infarction
時間枠:2 Year
|
Incidence of MI |
2 Year
|
|
Incidence of Life-threatening Bleeding
時間枠:2 Year
|
Incidence of life-threatening bleeding:
|
2 Year
|
|
Incidence of Prosthetic Valve Endocarditis
時間枠:2 Year
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
2 Year
|
|
Incidence of Prosthetic Valve Thrombosis
時間枠:2 Year
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
2 Year
|
|
Valve-related Dysfunction
時間枠:2 Year
|
Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II) |
2 Year
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:2 Year
|
Incidence of Valve-related dysfunction requiring repeat procedure |
2 Year
|
|
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
時間枠:2 year
|
Mean aortic gradient |
2 year
|
|
Valve Hemodynamic Performance Metric - Effective Orifice Area
時間枠:2 year
|
Effective orifice area |
2 year
|
|
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
時間枠:2 year
|
Degree of aortic regurgitation (transvalvular, paravalvular, total) |
2 year
|
|
New York Heart Association (NYHA) Functional Classification
時間枠:2 Year
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
2 Year
|
|
All-cause Mortality
時間枠:3 year
|
Percentage of participants with all-cause mortality |
3 year
|
|
All Stroke
時間枠:3 year
|
Incidence of stroke (disabling and non-disabling) |
3 year
|
|
Myocardial Infarction
時間枠:3 Year
|
Incidence of MI |
3 Year
|
|
Incidence of Life-threatening Bleeding
時間枠:3 Year
|
Incidence of life-threatening bleeding:
|
3 Year
|
|
Incidence of Prosthetic Valve Endocarditis
時間枠:3 Year
|
Incidence of prosthetic valve endocarditis: Any one of the following:
|
3 Year
|
|
Incidence of Prosthetic Valve Thrombosis
時間枠:3 Year
|
Incidence of Prosthetic valve thrombosis: Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. *Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis. |
3 Year
|
|
Valve-related Dysfunction
時間枠:3 Year
|
Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II) |
3 Year
|
|
Incidence of Valve-related Dysfunction Requiring Repeat Procedure
時間枠:3 Year
|
Incidence of Valve-related dysfunction requiring repeat procedure |
3 Year
|
|
Valve Hemodynamic Performance Metric - Mean Aortic Gradient
時間枠:3 year
|
Mean aortic gradient |
3 year
|
|
Valve Hemodynamic Performance Metric - Effective Orifice Area
時間枠:3 year
|
Effective orifice area |
3 year
|
|
Valve Hemodynamic Performance Metric - Degree of Aortic Regurgitation (Transvalvular, Paravalvular, Total)
時間枠:3 year
|
Degree of aortic regurgitation (transvalvular, paravalvular, total) |
3 year
|
|
New York Heart Association (NYHA) Functional Classification
時間枠:3 Year
|
New York Heart Association (NYHA) functional classification system is a tool that classifies patients with heart failure into one of four classes according to their degree of systems at rest and with activity. Below are the four classes and the associated patient symptoms (i.e., Class I has no limitations of physical activity vs. Class IV is most symptomatic and patient has symptoms of heart failure at rest). Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. |
3 Year
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Jianan Wang, MD、Second Affiliated Hospital, Zhejiang University, School of Medicine
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- MDT18065EVR009
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。